Order results by:
| Issue | Title | |
| Vol 17, No 2 (2025) | 12-year experience of incobotulinumtoxinA use in neurological practice | Abstract similar documents |
| N. V. Kireeva, E. G. Bukreeva, D. S. Kireev | ||
| "... various neurological conditions. IncobotulinumtoxinA is a purified BoNT-A, free from complexing proteins ..." | ||
| Vol 13, No 4 (2021) | IncobotulinumtoxinA in the treatment of sialorrhea in patients with infantile cerebral palsy | Abstract similar documents |
| A. L. Kurenkov, L. M. Kuzenkova, V. V. Chernikov, B. I. Bursagova, A. A. Nezhelskaya, A. R. Artemenko | ||
| "... : to evaluate the effectiveness of Xeomin (incobotulinumtoxinA) in the treatment of sialorrhea in patients ..." | ||
| Vol 14, No 2 (2022) | Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea | Abstract PDF (Eng) similar documents |
| A. L. Kurenkov, L. M. Kuzenkova, B. I. Bursagova, V. V. Chernikov, O. V. Agranovich, L. G. Khachatryan, V. M. Kenis, V. A. Zherebtsova, M. N. Sarzhina, N. D. Odinaeva, A. R. Artemenko, G. A. Popova, E. A. Moroshek, E. E. Tabe, A. A. Nezhelskaya, A. A. Maksimenko, L. Ya. Akhadova, M. V. Indereikin, N. V. Duibanova, L. V. Tikhonova, A. V. Sapogovskiy, Z. M. Gadzhialieva, A. V. Grigorieva, V. S. Perminov, I. D. Fedonyuk, L. M. Kolpakchi, A. Yu. Kursakova, N. A. Tsurina | ||
| "... on the efficacy and safety of incobotulinumtoxinA for the treatment of spasticity of the lower and upper limbs ..." | ||
| Vol 16, No 1 (2024) | Assessment of spasticity-related pain in cerebral palsy and the efficacy of its treatment with incobotulinumtoxin A (literature review) | Abstract similar documents |
| A. L. Kurenkov, B. I. Bursagova, A. R. Artemenko | ||
| "... analysis of data on the analgesic effect of the drug Xeomin (incobotulinumtoxin A) in the treatment of PAS ..." | ||
| Vol 14, No 1 (2022) | Treatment of spasticity in patients with the consequences of traumatic brain injury | Abstract similar documents |
| A. P. Kovalenko, I. A. Vozniuk, K. M. Naumov, V. Yu. Lobzin, S. Yu. Kirtaev | ||
| "... (mean – 650 U) of BoNT (incobotulinumtoxin) was injected into the spastic muscles of the upper and lower ..." | ||
| Vol 13, No 2 (2021) | Gait rehabilitation in patients with spastic hemiparesis: new opportunities | Abstract PDF (Eng) similar documents |
| A. P. Kovalenko, A. S. Rodionov, D. I. Kremlyov, D. V. Averkiev, V. Yu. Lobzin, A. V. Guseva | ||
| "... of BONT injections and ES exercises. Conclusion. ES ExoAtlet use is a promising technique for restoring ..." | ||
| Vol 17, No 2 (2025) | Use of botulinum toxin in patients with dysphagia and sialorrhea in acute ischemic stroke | Abstract similar documents |
| V. V. Gusev, T. V. Balueva, O. V. Zayceva, D. A. Smirnov | ||
| "... and increase the risk of aspiration pneumonia. Botulinum toxin type A (BoNT-A) injections are effective ..." | ||
| Vol 13, No 6 (2021) | Novel approaches to the treatment of cervical dystonia. The concept of dual navigation control | Abstract PDF (Eng) similar documents |
| A. P. Kovalenko, Z. A. Zalyalova, A. F. Ivolgin | ||
| "... ). Botulinum neurotoxin (BoNT) injections is the treatment choice for CD. However, the effectiveness ..." | ||
| Vol 12, No 5 (2020) | Cervical dystonia: current rehabilitation strategies and methods | Abstract similar documents |
| A. S. Istomina, I. V. Miliukhina, M. D. Didur | ||
| "... ботулинотерапии рассматриваются мультимодальная физиотерапевтическая программа, кинезиотейпирование, специальные и ..." | ||
| Vol 8, No 2 (2016) | Ultrasound-guided botulinum toxin injections | Abstract similar documents |
| S. E. Khatkova, A. A. Balbert | ||
| "... Одним из ключевых условий достижения желаемого результата при ботулинотерапии мышечной дистонии ..." | ||
| Vol 15, No 5 (2023) | Comprehensive diagnosis of cervical dystonia and the efficacy of long-term (three-year) botulinum therapy | Abstract similar documents |
| V. A. Tolmacheva, D. S. Petelin, B. A. Volel | ||
| "... диагностируется на поздних стадиях; эффективность длительной ботулинотерапии (БТ) при ЦД мало изучена. Цель ..." | ||
| Vol 14, No 3 (2022) | Hemimasticatory spasm: possibilities of treatment with injections of botulinum neuroprotein type A (case report) | Abstract similar documents |
| L. U. Valieva, A. S. Pankratov, O. R. Orlova | ||
| Vol 10, No 3 (2018) | Non-motor disorders in cervical dystonia | Abstract similar documents |
| V. A. Tolmacheva, M. R. Nodel, N. I. Saloukhna | ||
| Vol 12, No 3 (2020) | Arm spasticity after stroke: botulinum toxin therapy in combination with multimodal stimulation | Abstract similar documents |
| V. N. Lutsik, E. V. Slyunkova, S. V. Kotov, V. K. Misikov, E. V. Biryukova | ||
| Vol 13, No 1 (2021) | Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy | Abstract similar documents |
| Z. A. Zalyalova | ||
| "... движения и сенсомоторной дезинтеграции. Ботулинотерапия – наиболее эффективный метод лечения БФС ..." | ||
| Vol 14, No 6 (2022) | Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice | Abstract similar documents |
| R. K. Shikhkerimov, E. V. Istomina | ||
| "... природные свойства. Одним из показаний для применения ботулинотерапии в неврологии является коррекция ..." | ||
| Vol 16, No 1S (2024): Спецвыпуск: Головная боль | Evaluation of the efficacy of preventive therapy in chronic migraine with or without medication overuse headache: data from a prospective study | Abstract similar documents |
| E. A. Guziy, A. V. Sergeev, G. R. Tabeeva | ||
| "... , ботулинотерапия) или при использовании комбинированного варианта терапии по сравнению с монотерапией венлафаксином ..." | ||
| Vol 13, No 4 (2021) | Rehabilitation approaches in cervical dystonia | Abstract similar documents |
| Z. A. Zalyalova, E. R. Iusupova | ||
| Vol 12, No 6 (2020) | Mapping the limb muscle motor points for targeted administration of botulinum toxin in the treatment of focal and segmental spasticity | Abstract similar documents |
| A. P. Kovalenko, K. A. Sinelnikov, V. D. Shamigulov, N. N. Akhmedov, E. M. Shamina | ||
| "... injection of botulinum neurotoxin (BoNT) into the muscle motor points (MPs) is gaining more and more ..." | ||
| Vol 2, No 3 (2010) | Treatment for spasticity after stroke | Abstract similar documents |
| S. E. Khatkova | ||
| "... возможности ботулинотерапии постинсультной спастичности, в частности использование у таких больных ..." | ||
| Vol 16, No 6 (2024) | Updated and revised Russian consensus on the use of multilevel injections of abobotulinumtoxin A in children | Abstract similar documents |
| A. L. Kurenkov, O. A. Klochkova, V. A. Zmanovskaya, I. V. Falkovskiy, V. M. Kenis, L. N. Vladykina, D. A. Krasavina, A. S. Nosko, L. V. Rychkova, Kh. M. Karimova, B. I. Bursagova, L. S. Namazova-Baranova, A. M. Mamedyarov, L. M. Kuzenkova, O. G. Dontzov, M. A. Ryzhenkov, M. N. Butorina, D. M. Dankov, E. V. Levitina, D. A. Popkov, S. O. Ryabykh, O. V. Agranovich, T. I. Kiseleva, O. N. Vasileva, V. P. Zykov, V. I. Mihnovich, T. A. Belogorova | ||
| "... применение препаратов ботулинического токсина типа А (БТА). Международный опыт использования ботулинотерапии ..." | ||
| Vol 13, No 5 (2021) | Spasticity syndrome in cerebral pathology: evaluation and clinical models | Abstract PDF (Eng) similar documents |
| A. P. Kovalenko, I. A. Voznyuk, V. K. Misikov | ||
| "... neurotoxin (BoNT) administration schemes and creating spasticity models that could predict the drug ..." | ||
| Vol 14, No 4 (2022) | Anxiety-depressive spectrum disorders in cervical dystonia | Abstract similar documents |
| V. A. Tolmacheva, P. G. Yuzbashyan, D. S. Petelin, B. A. Volel, N. I. Salouhina, M. R. Nodel, D. V. Romanov | ||
| "... депрессивными проявлениями. Однако изменение эмоционального состояния пациентов с ЦД после ботулинотерапии ..." | ||
| Vol 9, No 3 (2017) | Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation | Abstract similar documents |
| P. N. Vlasov | ||
| "... (AEs) due to the increase in a blood drug concentrations and seizures as a result of its fall, which ..." | ||
| Vol 16, No 2 (2024) | Modelling long-term outcomes and mortality risk in patients with post-stroke spasticity during abobotulinum toxin injections as part of rehabilitation | Abstract similar documents |
| S. E. Khatkova, A. S. Gilweg | ||
| "... эффективность ботулинотерапии (инъекций абоботулотоксина – AбоБTA) на фоне проведения реабилитации у пациентов с ..." | ||
| Vol 5, No 3 (2013) | The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease | Abstract similar documents |
| Marina Romanovna Nodel | ||
| "... adverse events (AEs) include side effects typical for DRA, which are generally mild or moderate ..." | ||
| Vol 12, No 1 (2020) | Comparative efficacy and tolerance of centrally acting muscle relaxants in elderly patients with nonspecific musculoskeletal pain | Abstract similar documents |
| R. V. Gorenkov, M. N. Dadasheva, I. A. Zolotovskaya, V. A. Kruglov | ||
| "... , to check the coordinator system, and to record adverse events (AEs) were mandatory. Results and discussion ..." | ||
| Vol 11, No 4 (2019) | Antipsychotic-induced tardive dyskinesia as a serious adverse effect in the psychopharmacotherapy of schizophrenia | Abstract similar documents |
| E. E. Vaiman, N. A. Shnayder, N. G. Neznanov, R. F. Nasyrova | ||
| "... -induced adverse effects (AEs) that stigmatize patients and worsen quality of life. Tardive dyskinesia (TD ..." | ||
| Vol 16 (2024): (Suppl. 2) | Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis | Abstract similar documents |
| F. A. Khabirov, E. V. Granatov, A. Ya. Dykhanov, T. I. Khaibullin | ||
| "... on the occurrence of adverse events (AEs) and their severity as well as the frequency of discontinuation of the drug ..." | ||
| Vol 13, No 5 (2021) | Effectiveness of early abobotulinum toxin (Dysport®) injections in patients with upper limb spastic paresis after traumatic brain injury in real clinical practice: results of a multicenter observational non-interventional prospective study (Adults with post Traumatic Brain Injury (TBI) upper limb (UL) spasticity – APTULS) | Abstract similar documents |
| S. E. Khatkova, V. P. Diagileva, L. V. Krylova, D. V. Pokhabov, A. G. Arutiunian | ||
| "... ботулинотерапия является неотъемлемой частью комплексного лечения пациентов со спастичностью, обладает высоким ..." | ||
| Vol 8, No 4 (2016) | GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS | Abstract similar documents |
| T. E. Shmidt | ||
| "... (AEs). To improve treatment adherence to glatiramer acetate, its new 40-mg formulation has been ..." | ||
| Vol 15, No 5 (2023) | Efficacy and safety of Vespireit® (buspirone) prolonged-release tablets (PR) 15 mg in the therapy of patients with functional dizziness: results of the double-blind, placebo-controlled, multicenter, randomized, phase 3 clinical trial | Abstract similar documents |
| M. V. Zamergrad, V. A. Parfenov, A. S. Agafina, N. V. Lyamina, M. M. Gavrik, L. R. Kuchumova, E. R. Barantsevich, V. S. Krasnov, A. A. Ivanova, A. L. Vladykin, K. А. Ishchenko | ||
| "... in the clinical trial was monitoring of adverse events (AEs), clinically significant deviations in vital signs ..." | ||
| Vol 8, No 2 (2016) | Possibilities of using computed tomography to treat mixed cervical dystonia with botulinum toxin type A | Abstract similar documents |
| T. V. Mokina, Yu. I. Pavlov, Z. A. Zalyalova | ||
| "... только поверхностные, но и глубокие дистоничные мышцы шеи, уточнить схему ботулинотерапии, оценить ..." | ||
| Vol 14, No 1 (2022) | The efficacy and safety of ipidacrine in patients with idiopathic neuropathy of the facial nerve (PELICAN study) | Abstract similar documents |
| I. N. Samartsev, S. A. Zhivolupov, V. V. Ponomarev, M. N. Markova, K. R. Magomedov | ||
| "... ), электронейромиографии (ЭНМГ) и определения числа пациентов с показаниями к ботулинотерапии. Результаты и обсуждение ..." | ||
| Vol 12, No 3 (2020) | A Russian retrospective multicenter open-label observational study based on medical documentation on the use of perampanel in everyday clinical practice | Abstract PDF (Eng) similar documents |
| P. N. Vlasov, V. A. Karlov, I. A. Zhidkova, D. V. Dmitrenko, I. G. Rudakova, T. V. Danilova, V. A. Kalinin, O. V. Grebenyuk, A. P. Gertsen, Ya. S. Zhuravlev, A. Yu. Karas, E. N. Paramonova, I. V. Ponomareva, O. I. Miguskina, N. A. Sobyanina, D. V. Sukhova, Yu. V. Salomatin, M. L. Ertakhova, T. M. Goguadze, A. P. Shamray | ||
| "... , 72.3—89.1). Adverse events (AEs) were noted in 31.3% of patients; the most frequent AEs were ..." | ||
| Vol 15, No 3 (2023) | Clinical effectiveness and safety of prolonged release form of alimemazine in patients with generalized anxiety disorder | Abstract similar documents |
| Ju. E. Azimova, Yu. P. Sivolap, K. A. Ishchenko | ||
| "... to baseline, p<0.0001). The therapy was well tolerated, among the adverse events (AEs) patients noted: morning ..." | ||
| Vol 16, No 3 (2024) | Observational study of the effect of perampanel on sleep and daytime sleepiness in adult patients with epilepsy in real-life clinical practice | Abstract similar documents |
| P. N. Vlasov, V. A. Karlov, I. A. Zhidkova, M. A. Vagina, A. V. Vasilenko, T. M. Goguadze, T. V. Danilova, O. N. Kirillovskikh, I. Yu. Kovaleva, Yu. A. Kornukova, S. Yu. Lavrik, I. V. Larina, L. V. Lipatova, E. R. Tokareva, A. V. Ulitin, N. V. Filatova, M. A. Yamin | ||
| "... (Hospital Anxiety and Depression Scale, HADS), adverse events (AEs), efficacy/tolerability of combination ..." | ||
| Vol 16, No 1 (2024) | Treatment of cognitive impairment in patients with cerebral infarction in the internal carotid arteries circulation system: results of a multicentre, randomized, double-blind, placebo-controlled clinical trial | Abstract similar documents |
| D. R. Khasanova, A. A. Yakupova, P. R. Kamchatnov, Zh. Yu. Chefranova, E. I. Bogdanov, P. I Pilipenko, N. M. Khasanova | ||
| "... .0014]). 42 adverse events (AEs) were recorded in 32 (26.0%) patients in the Prospecta group and 37 AEs in 28 ..." | ||
| Vol 12, No 3 (2020) | The efficiency and tolerability of lacosamide therapy in adolescents and adults with new-onset focal epilepsy in terms of the epileptiform activity index | Abstract PDF (Eng) similar documents |
| V. A. Karlov, P. N. Vlasov, A. B. Kozhokaru, A. S. Samoilov, A. S. Orlova | ||
| "... . Adverse events (AEs) were assessed using the SIDe-effects of AntiEpileptic Drugs (SIDAED) questionnaire ..." | ||
| Vol 15, No 4 (2023) | Pharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio® | Abstract similar documents |
| A. S. Goncharov, A. V. Grigoriev, A. A. Globenko, I. S. Goncharov, K. A. Muratov, D. V. Yaroshenko, A. A. Sidorova, A. V. Kapashin, O. V. Kovchan, A. I. Bashkatova, M. A. Pasko | ||
| "... of the subjects were monitored, and the occurrence of adverse events (AEs) and serious AEs was recorded. Results ..." | ||
| Vol 15, No 6 (2023) | NOVEMA® NIGHT (diphenhydramine + naproxen) in patients with pain and insomnia: results of a multicenter non-interventional observational study | Abstract similar documents |
| A. B. Danilov, A. A. Pilipovich, M. V. Pyastolova | ||
| "... tolerated and no patient discontinued treatment due to adverse events (AEs). Conclusion. Short-term ..." | ||
| Vol 16, No 1 (2024) | Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine | Abstract similar documents |
| G. N. Belskaya, A. V. Krasnikov, E. A. Kiryanova, M. E. Prokopovich, E. V. Sakharova, G. V. Makarov | ||
| "... % or more, the impact of headache on daily activities (HIT-6 scale), adverse events (AEs) and tolerability ..." | ||
| Vol 17, No 2 (2025) | Multitarget transcranial magnetic theta-burst stimulation in the correction of cognitive impairment in patients with progressive multiple sclerosis | Abstract similar documents |
| A. Kh. Zabirova, I. S. Bakulin, A. G. Poydasheva, D. Yu. Lagoda, M. N. Zakharova, E. V. Gnedovskaya, N. A. Suponeva, M. A. Piradov | ||
| "... and questionnaires on subjective CI and fatigue. Results. No serious adverse events (AEs) or discontinuation of TMS ..." | ||
| Vol 14, No 5 (2022) | Safety of Mexidol® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups | Abstract similar documents |
| E. A. Ushkalova, S. K. Zyryanov, O. I. Butranova | ||
| "... To reduce the risk of developing adverse events (AEs) and increase the adherence of elderly ..." | ||
| Vol 13, No 6 (2021) | Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm® Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain | Abstract similar documents |
| V. A. Parfenov, E. I. Bogdanov, V. B. Laskov, N. S. Makarov, N. V. Pisova, E. A. Salina, Zh. Yu. Chefranova, L. V. Chichanovskaya | ||
| "... group. The presence of adverse events (AEs) was determined based on patient complaints and general ..." | ||
| Vol 12, No 3 (2020) | Experience with chondroitin sulfate in the combination therapy of lower back pain | Abstract similar documents |
| O. A. Shavlovskaya, I. D. Romanov, Yu. S. Prokofyeva | ||
| "... , during palpation), as well as the Oswestry functional status scale (OFSS). Adverse events (AEs) were ..." | ||
| Vol 16, No 3 (2024) | Therapeutic outcomes in patients with acute non-specific (musculoskeletal) pain according to the FORTE (ФОРТЕ) observational study | Abstract similar documents |
| V. A. Parfenov | ||
| "... with a low risk of chronic pain (p=0.002). A low incidence of adverse events (AEs) was observed when taking ..." | ||
| Vol 14, No 6 (2022) | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study | Abstract similar documents |
| Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova | ||
| "... -диагностический центр экстрапирамидной патологии и ботулинотерапии в г. Казань в период с октября 2021 г. по ..." | ||
| Vol 16, No 3 (2024) | Analyzing the predictors of relapse in drug-induced headache: a prospective clinical and psychological study | Abstract similar documents |
| E. A. Guziy, A. V. Sergeev, G. R. Tabeeva | ||
| "... , ботулинотерапия или вариант комбинированного лечения. ..." | ||
| Vol 15, No 6 (2023) | Non-interventional epidemiological program for investigating the real-life practice of using quetiapine (Seroquel®) in patients with schizophrenia and bipolar affective disorder (EPIDEMICUS) | Abstract similar documents |
| V. E. Medvedev, I. G. Kuznetsova | ||
| "... medications by psychiatric patients, as well as the frequent development of adverse events (AEs), require ..." | ||
| 1 - 50 of 50 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
